Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings)

In the last three months, 7 analysts have published ratings on Travere Therapeutics TVTX, offering a diverse range of perspectives from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $12.71, with a high estimate of $20.00 and a low estimate of $7.00. Marking an increase of 18.23%, the current average surpasses the previous average price target of $10.75.

Investigating Analyst Ratings: An Elaborate Study

A comprehensive examination of how financial experts perceive Travere Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Travere Therapeutics. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Travere Therapeutics compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Travere Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Travere Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Travere Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Travere Therapeutics

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Financial Milestones: Travere Therapeutics's Journey

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Travere Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 32.13%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Travere Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 406.35% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Travere Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 76.08% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Travere Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 19.21%, the company showcases efficient use of assets and strong financial health.

Debt Management: Travere Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 1.45. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

Analyst Ratings: What Are They?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.